Lipocine Inc. (www.lipocine.com) announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products. LPCN 1021 is licensed to Abbott Products.
“Addition of these applications in conjunction with our several issued patents has significantly strengthened our intellectual property portfolio for LPCN 1021.”
Dr. Mahesh V. Patel, President and Chief Executive Officer of Lipocine Inc., commented, "Addition of these applications in conjunction with our several issued patents has significantly strengthened our intellectual property portfolio for LPCN 1021."
It is estimated that hypogonadism, also known as low testosterone, affects more than 13 million men in the United States age 45 and older. Because signs and symptoms of low testosterone are subtle and often overlap with other common medical conditions, low testosterone is frequently undiagnosed.
As evidenced by the substantial recent expansion of testosterone market exceeding $1.2 billion in the US, there is an increased awareness of hypogonadism. Signs and symptoms of low testosterone may include low sex drive, erectile dysfunction, fatigue, depressed mood, reduced muscle mass and strength, increased fat body mass and decreased bone mineral density.
Study reveals how sex hormones regulate immune system functions